+

WO2001027136A3 - Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire - Google Patents

Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire Download PDF

Info

Publication number
WO2001027136A3
WO2001027136A3 PCT/FR2000/002786 FR0002786W WO0127136A3 WO 2001027136 A3 WO2001027136 A3 WO 2001027136A3 FR 0002786 W FR0002786 W FR 0002786W WO 0127136 A3 WO0127136 A3 WO 0127136A3
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
stimulate
peptides
immune response
glu
Prior art date
Application number
PCT/FR2000/002786
Other languages
English (en)
Other versions
WO2001027136A2 (fr
Inventor
Denis Barritault
Ammar Achour
Jose Courty
Original Assignee
Centre Nat Rech Scient
Denis Barritault
Ammar Achour
Jose Courty
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Denis Barritault, Ammar Achour, Jose Courty filed Critical Centre Nat Rech Scient
Priority to AU77955/00A priority Critical patent/AU7795500A/en
Priority to EP00967971A priority patent/EP1222201A2/fr
Priority to JP2001530354A priority patent/JP2004502636A/ja
Priority to CA002387604A priority patent/CA2387604A1/fr
Publication of WO2001027136A2 publication Critical patent/WO2001027136A2/fr
Publication of WO2001027136A3 publication Critical patent/WO2001027136A3/fr
Priority to US10/116,391 priority patent/US6932973B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention se rapporte à un peptide répondant à la formule (I): (A)n - A1A1 - A2 - A1 - A3 - A4 - A1 - (A)m dans laquelle : A est un acide aminé quelconque, n et m sont chacun des nombres entiers de 0 à 20 dont la somme n + m est comprise entre 0 et 20, de préférence entre 0 et 15 et tout préférentiellement entre 0 et 10, A1 est un acide aminé basique et plus particulièrement la lysine (Lys) ou l'arginine (Arg), A2 est un acide aminé choisi parmi : les acides aminés basiques, l'acide glutamique (Glu), la glycine (Gly), l'acide aspartique (Asp), A3 est un acide aminé choisi parmi : les acides aminés basiques, la proline (Pro), l'acide glutamique (Glu), la glutamine (Gln), A4 est un acide aminé choisi parmi : les acides aminés basiques, l'acide glutamique (Glu), la glycine (Gly), la sérine (Ser), la valine (Val).
PCT/FR2000/002786 1999-10-12 2000-10-06 Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire WO2001027136A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU77955/00A AU7795500A (en) 1999-10-12 2000-10-06 Peptides which stimulate the immune response and tissue regeneration
EP00967971A EP1222201A2 (fr) 1999-10-12 2000-10-06 Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
JP2001530354A JP2004502636A (ja) 1999-10-12 2000-10-06 免疫応答及び組織の再生を活性化するペプチド
CA002387604A CA2387604A1 (fr) 1999-10-12 2000-10-06 Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
US10/116,391 US6932973B2 (en) 1999-10-12 2002-04-04 Peptides which stimulate the expression of the cytokines of inflammation and promote tissue regeneration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9912714A FR2799465B1 (fr) 1999-10-12 1999-10-12 Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
FR99/12714 1999-10-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/116,391 Continuation US6932973B2 (en) 1999-10-12 2002-04-04 Peptides which stimulate the expression of the cytokines of inflammation and promote tissue regeneration

Publications (2)

Publication Number Publication Date
WO2001027136A2 WO2001027136A2 (fr) 2001-04-19
WO2001027136A3 true WO2001027136A3 (fr) 2001-12-13

Family

ID=9550838

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2000/002786 WO2001027136A2 (fr) 1999-10-12 2000-10-06 Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire

Country Status (7)

Country Link
US (1) US6932973B2 (fr)
EP (1) EP1222201A2 (fr)
JP (1) JP2004502636A (fr)
AU (1) AU7795500A (fr)
CA (1) CA2387604A1 (fr)
FR (1) FR2799465B1 (fr)
WO (1) WO2001027136A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0026134D0 (en) 2000-10-25 2000-12-13 Eurogene Ltd Peptides and their use
AU2002362185A1 (en) 2002-01-09 2003-07-30 Suntory Limited SUGAR TRANSFERASE GnT-V HAVING ANGIOGENIC EFFECT
FR2846659B1 (fr) 2002-10-30 2005-02-18 Centre Nat Rech Scient Fragments peptidiques du facteur harp inhibant l'angiogenese
DE10355559A1 (de) * 2003-11-21 2005-06-23 Orthogen Ag Transskin
US20090312265A1 (en) * 2006-02-10 2009-12-17 Dermagen Ab Novel antimicrobial peptides and use thereof
SI2280720T1 (sl) 2008-03-27 2019-06-28 Purdue Research Foundation Sintetični peptidoglikani,ki vežejo kolagen, priprava in postopki uporabe
WO2009153418A1 (fr) * 2008-06-16 2009-12-23 Centre National De La Recherche Scientifique (C.N.R.S) Peptides harp inhibant la croissance tumorale
WO2011115562A1 (fr) * 2010-03-18 2011-09-22 Egesten Medical Consulting Hb Composé antimicrobien
FR2957799B1 (fr) 2010-03-26 2012-08-17 Inst Des Vaisseaux Et Du Sang Compositions proangiogeniques, leur procede de preparation et leurs utilisations
CN103732614B (zh) 2011-05-24 2016-08-17 塞米克Ip有限公司 结合透明质酸的合成肽聚糖、制备和使用方法
EP2970509B1 (fr) 2013-03-15 2020-05-13 Purdue Research Foundation Peptidoglycanes synthétiques de liaison à la matrice extracellulaire
US10772931B2 (en) 2014-04-25 2020-09-15 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
JP2020526497A (ja) 2017-07-07 2020-08-31 サイミック アイピー， エルエルシー 合成バイオコンジュゲート
CN117244043B (zh) * 2023-11-02 2024-09-20 徐州医科大学附属医院 破伤风类毒素在治疗血管内皮细胞损伤中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665448A1 (fr) * 1990-08-01 1992-02-07 Paris Val De Marne Universite Procede d'obtention d'un peptide ayant une activite facteur de croissance, produit obtenu et son application comme medicament.
FR2701955A1 (fr) * 1993-02-26 1994-09-02 Paris Val Marne Universite Facteur de croissance de la famille de l'HARP, procédé d'obtention et applications.
WO1998008856A2 (fr) * 1996-08-30 1998-03-05 Fuerste Jens Peter Selection et evolution speculaires d'acides nucleiques
US5736294A (en) * 1990-03-21 1998-04-07 Isis Pharmaceuticals, Inc. Reagents and methods for modulating gene expression through RNA mimicry
WO1998039037A1 (fr) * 1997-03-03 1998-09-11 Beth Israel Deaconess Medical Center Liaison in-vivo simultanee d'immunoconjugues a de multiples epitopes du facteur de permeabilite vasculaire sur des vaisseaux sanguins associes a des tumeurs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294322B1 (en) * 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
NZ336838A (en) * 1997-01-29 2002-04-26 Cornell Res Foundation Inc A method of enhancing the level of perfusion of blood to a target tissue by administering an adenoviral vector encoded with an angiogenic peptide within 0.5-15 cm3 of the tissue

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736294A (en) * 1990-03-21 1998-04-07 Isis Pharmaceuticals, Inc. Reagents and methods for modulating gene expression through RNA mimicry
FR2665448A1 (fr) * 1990-08-01 1992-02-07 Paris Val De Marne Universite Procede d'obtention d'un peptide ayant une activite facteur de croissance, produit obtenu et son application comme medicament.
FR2701955A1 (fr) * 1993-02-26 1994-09-02 Paris Val Marne Universite Facteur de croissance de la famille de l'HARP, procédé d'obtention et applications.
WO1998008856A2 (fr) * 1996-08-30 1998-03-05 Fuerste Jens Peter Selection et evolution speculaires d'acides nucleiques
WO1998039037A1 (fr) * 1997-03-03 1998-09-11 Beth Israel Deaconess Medical Center Liaison in-vivo simultanee d'immunoconjugues a de multiples epitopes du facteur de permeabilite vasculaire sur des vaisseaux sanguins associes a des tumeurs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JONCA, FREDERIC ET AL: "Cell release of bioactive fibroblast growth factor 2 by exon 6-encoded sequence of vascular endothelial growth factor", J. BIOL. CHEM. (1997), 272(39), 24203-24209, 26 September 1997 (1997-09-26), XP002141912 *

Also Published As

Publication number Publication date
US6932973B2 (en) 2005-08-23
JP2004502636A (ja) 2004-01-29
AU7795500A (en) 2001-04-23
US20030087255A1 (en) 2003-05-08
EP1222201A2 (fr) 2002-07-17
WO2001027136A2 (fr) 2001-04-19
FR2799465B1 (fr) 2004-02-13
FR2799465A1 (fr) 2001-04-13
CA2387604A1 (fr) 2001-04-19

Similar Documents

Publication Publication Date Title
WO1997008199A3 (fr) Peptides cationiques antimicrobiens et procedes de reconnaissance de ceux-ci
WO2001027136A3 (fr) Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
WO1999015549A3 (fr) Peptides
WO1995003327A3 (fr) Peptides de neutralisation de la toxicite du lipide a
EP0873754A4 (fr) Compositions d'acides amines
CA2061569A1 (fr) Activation de proteines recombinantes
CA2111645A1 (fr) Peptides e a fragment fibrinogene et leurs anticorps
WO2001005810A3 (fr) DERIVES PEPTIDIQUES CYCLIQUES SERVANT D'INHIBITEURS DE L'INTEGRINE αVβ¿6?
WO2002008426A3 (fr) Proteine
EP1006126A3 (fr) Peptide possedant une activité ostéogénique
EP0506628A3 (fr) Dérivés de l'allopurinol aminoacylés et oligopeptides à activité immunostimulatrice et compositions pharmaceutiques les contenant
WO1994026903A3 (fr) Peptides du virus de la grippe chez l'homme se fixant a une molecule de hla-i
ATE245168T1 (de) Peptide, die anti-zellanhaftungsaktivität aufweisen
AU2957099A (en) Novel physiologically active peptides and utilization thereof
AU585167B2 (en) Novel substrate peptides
DK1519951T3 (da) Kationiske ligekædede peptider med antifungale egenskaber
EP1908781A3 (fr) Modulation d'une réponse immunitaire et procédés basés sur cette modulation
CA2259640A1 (fr) Vecteur de glycine humaine
CA2057612A1 (fr) Peptides selectionnes de l'antigene specifique au groupe (gag) du virus de l'immunodeficience humaine (vih), sa preparation et son utilisation
WO2002030975A3 (fr) Composé fongicide
EP0361956A3 (fr) Expression augmentée de protéines recombinantes à faible poids moléculaire
WO2004000870A3 (fr) Deux peptides synthetiques pour le traitement et la prevention de cancers
EP0959895A4 (fr) Peptides sensibles a des anticorps diriges contre un peptide consensus des proteines de la famille c54-cfa/i
WO2001042423A3 (fr) Compositions et procedes servant a detecter des proteines de stress
EP1225184A4 (fr) Variants d'antithrombine humaine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10116391

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2001 530354

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000967971

Country of ref document: EP

Ref document number: 2387604

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2000967971

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载